Genocea Biosciences Inc. buy mixitrader
Summary
This prediction ended on 08.01.22 with a price of €0.94. The price of Genocea Biosciences Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -29.85%. mixitrader has 50% into this predictionGenocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Genocea Biosciences Inc. | - | - | - |
| iShares Core DAX® | 0.961% | -2.210% | 12.839% |
| iShares Nasdaq 100 | 2.626% | -1.918% | 38.498% |
| iShares Nikkei 225® | 0.217% | -7.216% | 19.425% |
| iShares S&P 500 | 1.540% | -1.858% | 27.801% |
Comments by mixitrader for this prediction
In the thread Genocea Biosciences Inc. diskutieren
In the thread Trading Genocea Biosciences Inc.